Synlogic, Inc.

SYBX Healthcare Biotechnology

Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.00 0.08 −7.41%
Market cap
$6.7M
P/E
0.0×
Fwd P/E
−2.8×
Dividend yield
—
F-score
3/9
Altman Z
−35.79
Beneish M
n/a
Dividend safety
n/a

Synlogic, Inc. (SYBX) P/E ratio

Alert me on P/E ratio

Synlogic, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 6.1× (June 2025) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Mar 2024 0.0× —
Dec 2023 0.0× —
Sep 2023 0.0× —
Jun 2023 0.0× —
25 more quarters

Against its own ten years

Low 0.0× High 6.1×
Ten-year median 0.0×
Current reading's percentile 89

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on SYBX